Global pharmaceutical company Allergan Aesthetics, an AbbVie company, has entered into an exclusive development and commercialisation agreement with regenerative medicine company CollPlant to use its plant-derived recombinant human collagen.
Allergan explains that the collagen (rhCollagen) will be used in combination with its proprietary technologies, for the production and commercialisation of dermal and soft tissue fillers.
Yehiel Tal, chief executive officer of CollPlant, commented, "We are very pleased to formalise this collaboration with Allergan Aesthetics, the worldwide leader in dermal and soft tissue fillers. We believe that combining technologies from Allergan Aesthetics and CollPlant will create a paradigm shift in the medical aesthetics field. CollPlant's rhCollagen is non-immunogenic and non-allergenic, and offers better tissue regeneration performance over animal-derived collagen which is currently used in medical aesthetics. This agreement further validates CollPlant's technology as the gold standard collagen for regenerative and aesthetic medicine. We look forward to a highly productive partnership."